Sudhaa Devi, P V (2022) Phase II Non Randomised Open Clinical Evaluation of Siddha Medicine Chanthirothaya Mathirai for the Management of Uthiravatha Suronitham (Rheumatoid Arthritis). Masters thesis, Government Siddha Medical College, Chennai.
|
Text
3201 015 22 321911109 Sudhaadevi P V.pdf Download (18MB) | Preview |
Abstract
An open clinical evaluation of siddha drug Chanthirothaya Mathirai in Uthiravatha Suronitham (Rheumatoid Arthritis) was conducted from 2019 to 2022 in the Post Graduate Department of Maruthuvam in Govt. Siddha Medical College attached with Arignar Anna Govt. Hospital of Indian Medicine, Chennai-106. A total of 20 cases were treated in Outpatient department. The clinical and Pathological assessment was carried out on the basis of Siddha and Modern aspects. All the patients were treated with Chanthirothaya Mathirai 1 Tablets/bds with Indhuppu legiyam after food for duration of 48 days. The responses were assessed once in 7 days for all the patients. ❖ The toxicological study revealed no toxicity in study drug Chanthirothaya Mathirai. ❖ The pharmacological study of Chanthirothaya Mathirai shows Anti-arthritic activity in Freund's adjuvant induced Arthritis in Wister rats. ❖ The peak incidence of Uthiravatha suronitham was in the age group of 31-50 years of both sexes. ❖ High incidence occurs in women (Female dominant disease) (92.5%). ❖ The disease is more common in office working (25%), housewives (20%) and labour (30%). ❖ The prevalence was higher among the lower middle-income group (37.5%). ❖ Regarding diet, the disease is seen among mixed dietary habits of about 87.5%. ❖ Regarding family history, 90% had no relevant family history. ❖ Most of the patients were affected in Pitha kaalam (85%). ❖ The disease is more common in Vatha kabha yaakkai cases (45%). ❖ Most of the patients were suffered from sub-acute illness with 6 months to 3 years of onset (70%). ❖ In Vatham Before treatment Pranan (90%), Abanan (75%), Viyanan (100%), Samanan (100%), Kirukaran (85%) Devathathan (70%) were affected. After the treatment with study drug 90%, 85%, 60%, 60%, 92.5%, 90% were improved respectively. ❖ In Pitham Before treatment Pasagam (80%), Ranjagam (100%), Saathagam (92.5%) were affected. After the treatment with study drug 90%, 85%, 87.5% were improved respectively. ❖ In Kabam Before treatment Avalambagam (100%), Kilethagam (92.5%), and Santhigam (100%) were affected. After treatment 90%, 87.5% and 85% were improved respectively. ❖ In Ezhu Udal Kattugal Before treatment Saaram (100%), Senneer (100%), Oon (100%), Kozhuppu (100%), Enbu (100%) were affected. After the treatment with study drug 90%, 85%, 87.5%, 85%, 80% were improved respectively. ❖ According to the study, Envagai thervugal Naa (15%), Niram (5%), Vizhi (5%), Sparisam (45%), Malam (30%) were affected. ❖ Regarding Naadi, Kaba vatha naadi (45%), Vatha kaba naadi (30%) was the most common naadi observed. ❖ In Neikuri examination, Vatha neer (75%) were observed. ❖ Statistical analysis of clinical features revealed that the p-value is <0.05 there is significant difference between the before treatment and after treatment values, hence the null hypothesis is rejected and accepting the alternative hypothesis. ❖ This shows that the given drug Chanthirothaya Mathirai is significant for the treatment of Rheumatoid Arthritis. ❖ Statistical analysis of Anti CCP in the current study revealed that the p value is <0.05, there is a significant difference between the mean anti CCP level before and after treatment. ❖ According to CRP, the p value is <0.05, there is a significant difference between the mean CRP level before and after treatment. ❖ The outcome of study revealed that among the 40 study participants, 80% had good response, 12.5% had moderate response and 7.5% had poor response. CONCLUSION: Uthiravatha Suronitham (Rheumatoid Arthritis) occurs due to derangement of Vatham. Taste and Veppa Veeriyam of ingredients in "Chanthirothaya Mathirai” to neutralize the Uthiravatha Suronitham noi. The toxicological studies of study drug revealed no toxicity in animal models and hence proved to be safe in human subjects. The Pharmacological studies revealed that treatment with Chanthirothaya Mathirai at both the dose level have shown significant decrease in the paw volume and paw edema. So, it possesses the Anti arthritic activity. A wide variety of patients with Pain, swelling in the joints, Morning stiffness, Tenderness, Low grade fever, Constipation, Loss of appetite, Depression were selected. After administration of the drug, there is remarkable reduction in clinical symptoms and laboratory parameters. After treatment without any adverse effects has been distinguished. So, the author concludes that this study clearly demonstrated the safety and efficacy of Chanthirothaya Mathirai in the management of Uthiravatha Suronitham (Rheumatoid Arthritis) in both male and female. As the author had certain limitations in sample size & duration for conducting the study, the author decides to do in large sample size with long term duration in upcoming years. The Drug is very cost effective and palatable, so it can be utilized for huge population in the public health sector.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg.No.321911109 |
| Uncontrolled Keywords: | Phase II Non Randomised Open Clinical Evaluation, Siddha Medicine, Chanthirothaya Mathirai, Management, Uthiravatha Suronitham, Rheumatoid Arthritis. |
| Subjects: | AYUSH > Maruthuvam |
| Depositing User: | Subramani R |
| Date Deposited: | 01 May 2023 06:19 |
| Last Modified: | 13 Feb 2024 05:35 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/21137 |
Actions (login required)
 |
View Item |
